Tag: COVID-19
Acquired Weakness and Hospital Functional Mobility Outcomes Following Invasive Mechanical Ventilation in Patients with COVID-19
In critically ill COVID-19 patients, the incidence of ICUAW and acute gait dependence were high. Our study identifies factors influencing both outcomes. Future studies should investigate optimal COVID-19 ARDS management and... read more
Disposable Hospital Gowns May Pose Infection Risk
Disposable gowns designed to deflect the splatter of bodily fluids, used in thousands of U.S. hospitals, have underperformed in recent and ongoing laboratory tests and may fall short of safety standards, leaving health care... read more
Prevalence of PICS in Mechanically Ventilated Patients with COVID-19
Coronavirus disease 19 (COVID-19) patients usually require long periods of mechanical ventilation and sedation, which added to steroid therapy, favours a predisposition to the development of delirium and subsequent mental... read more
The Mysterious Vanishing of MIS-C
Whilst the overwhelming majority of Covid-19 infections in healthy children are mild or asymptomatic, the serious risk which remained was of the hyperinflammatory syndrome known as MIS-C (Multi-system Inflammatory Syndrome... read more
Pericarditis and Myocarditis in the ED
Chest pain is one of the most common presentations to the emergency department (ED) and includes a wide differential diagnosis. In today’s post, we will review a less common cause of chest pain seen in the ED: pericarditis... read more
Hydroxychloroquine Not Associated With Decreased Risk for COVID-19 Hospitalization
Results of a multicenter, double-blinded, randomized controlled trial found no evidence to support the use of hydroxychloroquine for COVID-19 infection in the outpatient setting. These findings were published in The Lancet... read more
Majority of Family Members of COVID-19 Patients Treated in the ICU Report PTSD Symptoms
A majority of family members of COVID-19 patients treated in ICUs reported significant symptoms of post-traumatic stress disorder in the following months, according to a study published Monday that sheds new light on the... read more
Inflammation Causes COVID-19-related Loss of Smell Not The Virus
This study found that COVID-19 infection is associated with axon injuries and microvasculopathy in olfactory tissue. The striking axonal pathology in some cases indicates that olfactory dysfunction in COVID-19 infection may... read more
Risk of Serious Blood Clots Up To 6 Months After COVID-19
A study from Sweden finds an increased risk of deep vein thrombosis (a blood clot in the leg) up to three months after COVID-19 infection, pulmonary embolism (a blood clot in the lung) up to six months, and a bleeding event... read more
Post COVID-19 Pulmonary Fibrosis
Pulmonary fibrosis is a frequently reported COVID-19 sequela in which the exact prevalence and risk factors are yet to be established. This meta-analysis aims to investigate the prevalence of post-COVID-19 pulmonary fibrosis... read more
Myopericarditis Following COVID-19 Vaccination and Non-COVID-19 Vaccination
The overall incidence of myopericarditis from 22 studies (405,272,721 vaccine doses) was 33·3 cases (95% CI 15·3–72·6) per million vaccine doses, and did not differ significantly between people who received COVID-19... read more
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19
Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support–free days within 21 days. The... read more
External Chest-wall Compression in Prolonged COVID-19 ARDS with Low-compliance
SARS-CoV-2 can lead to severe respiratory failure (C-ARDS) with some clinical and radiological characteristics that match the presentation of acute respiratory distress syndrome (ARDS). The management of mechanical ventilation... read more
Prevalence of COVID-19-Associated Pulmonary Aspergillosis
First reports of cases and case series of COVID-19-associated pulmonary aspergillosis (CAPA) emerged during the first months of the pandemic. Prevalence rates varied widely due to the fact that CAPA was, and still remains,... read more
How Autoimmune Disease Risks Increases After COVID-19
The link between COVID-19 infection and development of autoimmune disease is becoming more pronounced, and fields including dermatology are seeking answers to what drives it all. A late-breaking session at the American... read more
tPA for Critically Ill ICU Patients with COVID-19: Does Alteplase Help?
How do you define a last-ditch effort to save someone's life from COVID-19? Perhaps giving tPA to a severe COVID patient? At this point, I am certain many of us have attempted, with informed consent of course, therapies for... read more
Thromboinflammation and Antithrombotics in COVID-19
Thrombotic complications of SARS-CoV-2 infection were recognized early in the pandemic, when infected patients often presented with abnormal coagulation findings and acute macrovascular obstruction, and evidence of pulmonary... read more
Music Therapy Intervention to Treat Sedation-Related Delirium in Critical Care
Sedation is an essential component of treatment for some patients admitted to the intensive care unit, but it carries a risk of sedation-related delirium. Sedation-related delirium is associated with higher mortality and... read more
Risks and Burdens of Incident Diabetes in Long COVID
In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during... read more
Comparative analysis of the risks of hospitalisation and death associated with COVID-19 variants in England
The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. Underlying the observed risks... read more
Association Between Dexamethasone Treatment for COVID-19 Patients and Rates of Hospital Readmission and Mortality
Current guidelines recommend use of dexamethasone, 6 mg/d, up to 10 days or until discharge for patients hospitalized with COVID-19. Whether patients who received less than 10 days of corticosteroids during hospitalization... read more
